share_log

葫芦娃:获得吸入用乙酰半胱氨酸溶液药品注册证书

Hainan Huluwa Pharmaceutical Group: obtained the pharmaceutical registration certificate for inhaled N-acetylcysteine solution.

Breakings ·  Aug 27 20:04

Hainan Huluwa Pharmaceutical Group announced that the company recently received the 'Pharmaceutical Registration Certificate' issued by the National Medical Products Administration for the inhaled N-acetylcysteine solution. This pharmaceutical is used to treat respiratory diseases with excessive thick mucus secretion, such as acute bronchitis, chronic bronchitis and its exacerbation, emphysema, viscous material obstruction, and bronchiectasis. The pharmaceutical has been evaluated and approved based on the technical requirements consistent with the quality and efficacy of the reference formulation, and its approval is considered equivalent to passing the evaluation of consistency in quality and efficacy of generic medicines. The company has cumulatively invested RMB 4.0207 million in research and development costs for this product. Obtaining the 'Pharmaceutical Registration Certificate' this time will further enrich the company's product line and play a positive role in the company's development.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment